US FDA extends review of Capricor's muscle disorder therapy by three months

Capricor Therapeutics said on Monday ​that the U.S. Food and Drug ‌Administration had extended the review of its experimental cell therapy for Duchenne muscular ​dystrophy by three months.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。